佰仁医疗
(688198)
| 流通市值：156.85亿 | | | 总市值：156.85亿 |
| 流通股本：1.38亿 | | | 总股本：1.38亿 |
| 报告期 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 248,028,217.88 | 100,139,512.37 | 501,879,121.74 | 292,324,016.69 |
| 营业收入 | 248,028,217.88 | 100,139,512.37 | 501,879,121.74 | 292,324,016.69 |
| 二、营业总成本 | 189,298,122.56 | 80,035,115.12 | 362,250,854.74 | 245,184,032.93 |
| 营业成本 | 28,419,837.35 | 14,300,970.48 | 58,524,711.44 | 33,427,904.06 |
| 税金及附加 | 4,299,784.13 | 1,344,071.21 | 4,198,830.33 | 2,384,147.13 |
| 销售费用 | 62,141,524.23 | 23,410,959.55 | 121,961,231.76 | 81,737,233.26 |
| 管理费用 | 21,060,792.38 | 8,399,826.52 | 32,960,162.42 | 22,407,154.06 |
| 研发费用 | 74,131,914 | 33,115,530.01 | 151,441,921.38 | 108,992,107.86 |
| 财务费用 | -755,729.53 | -536,242.65 | -6,836,002.59 | -3,764,513.44 |
| 其中:利息费用 | 429,950.77 | 106,564.61 | 462,630.48 | 358,594.35 |
| 其中:利息收入 | 1,424,794.99 | 731,930.22 | 7,309,673.95 | 4,789,476.85 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 8,921.33 | 497,473.03 | 742,302.66 | 643,981.26 |
| 加:投资收益 | 4,838,321.34 | 1,981,442.39 | 10,011,207.19 | 7,632,128.6 |
| 资产处置收益 | 1,753.37 | - | 362.99 | 149.61 |
| 信用减值损失(新) | 679,924.75 | 67,144.98 | -2,488,383.41 | -612,526.8 |
| 其他收益 | 16,640,381.75 | 14,490,211.75 | 5,326,472.29 | 4,366,528.65 |
| 四、营业利润 | 80,899,397.86 | 37,140,669.4 | 153,220,228.72 | 59,170,245.08 |
| 加:营业外收入 | 178,511.43 | 34,634.14 | 47,054.01 | 46,436.46 |
| 减:营业外支出 | 4,673,951.37 | 2,500,000 | 2,481,067.58 | 2,170,714.35 |
| 五、利润总额 | 76,403,957.92 | 34,675,303.54 | 150,786,215.15 | 57,045,967.19 |
| 减:所得税费用 | 10,944,558.43 | 4,493,024.89 | 18,642,719.46 | 7,040,113.52 |
| 六、净利润 | 65,459,399.49 | 30,182,278.65 | 132,143,495.69 | 50,005,853.67 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 65,459,399.49 | 30,182,278.65 | 132,143,495.69 | 50,005,853.67 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 71,400,619.61 | 32,504,318.17 | 146,330,147.71 | 58,693,362.23 |
| 少数股东损益 | -5,941,220.12 | -2,322,039.52 | -14,186,652.02 | -8,687,508.56 |
| 扣除非经常损益后的净利润 | 61,398,330.64 | 23,058,724.48 | 142,103,787.1 | 55,311,635.5 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.52 | 0.24 | 1.07 | 0.43 |
| (二)稀释每股收益 | 0.52 | 0.24 | 1.07 | 0.43 |
| 八、其他综合收益 | -74,321.8 | -32,950.47 | 320,537.92 | -296,622.83 |
| 归属于母公司股东的其他综合收益 | -74,321.8 | -32,950.47 | 320,537.92 | -296,622.83 |
| 九、综合收益总额 | 65,385,077.69 | 30,149,328.18 | 132,464,033.61 | 49,709,230.84 |
| 归属于母公司股东的综合收益总额 | 71,326,297.81 | 32,471,367.7 | 146,650,685.63 | 58,396,739.4 |
| 归属于少数股东的综合收益总额 | -5,941,220.12 | -2,322,039.52 | -14,186,652.02 | -8,687,508.56 |
| 公告日期 | 2025-08-28 | 2025-04-25 | 2025-04-25 | 2024-10-30 |
| 审计意见(境内) | | | 标准无保留意见 | |